157 related articles for article (PubMed ID: 11036471)
1. Antisense approaches for the treatment of cancer.
Monia BP; Holmlund J; Dorr FA
Cancer Invest; 2000; 18(7):635-50. PubMed ID: 11036471
[No Abstract] [Full Text] [Related]
2. Clinical studies of antisense oligonucleotides for cancer therapy.
Orr RM; Dorr FA
Methods Mol Med; 2005; 106():85-111. PubMed ID: 15375314
[No Abstract] [Full Text] [Related]
3. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.
Green DW; Roh H; Pippin J; Drebin JA
J Am Coll Surg; 2000 Jul; 191(1):93-105. PubMed ID: 10898188
[No Abstract] [Full Text] [Related]
5. Antisense oligonucleotides in lung cancer.
Pujol JL; Jacot W
Suppl Tumori; 2002; 1(4):S50-1. PubMed ID: 12415820
[No Abstract] [Full Text] [Related]
6. Antisense therapy in clinical oncology: preclinical and clinical experiences.
Tamm I
Methods Mol Med; 2005; 106():113-34. PubMed ID: 15375315
[No Abstract] [Full Text] [Related]
7. Antisense approaches in drug discovery and development.
Rayburn E; Wang W; Zhang R; Wang H
Prog Drug Res; 2005; 63():227-74. PubMed ID: 16265883
[No Abstract] [Full Text] [Related]
8. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
9. Selective gene therapy for proliferative disorders: sense and antisense.
Indolfi C; Chiariello M; Avvedimento EV
Nat Med; 1996 Jun; 2(6):634-5. PubMed ID: 8640548
[No Abstract] [Full Text] [Related]
10. Antisense approaches enter the clinic.
Khuri FR; Kurie JM
Clin Cancer Res; 2000 May; 6(5):1607-10. PubMed ID: 10815875
[No Abstract] [Full Text] [Related]
11. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
Stewart A
Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683
[No Abstract] [Full Text] [Related]
12. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
13. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
Roychowdhury D; Lahn M
Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
15. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
[TBL] [Abstract][Full Text] [Related]
17. Antisense cancer therapy: the state of the science.
Kushner DM; Silverman RH
Curr Oncol Rep; 2000 Jan; 2(1):23-30. PubMed ID: 11122821
[TBL] [Abstract][Full Text] [Related]
18. Antisense--time to shoot the messenger.
Kuss B; Cotter F
Ann Oncol; 1999 May; 10(5):495-503. PubMed ID: 10415997
[No Abstract] [Full Text] [Related]
19. Antisense strategies targeting protein kinase C: preclinical and clinical development.
Tortora G; Ciardiello F
Semin Oncol; 2003 Aug; 30(4 Suppl 10):26-31. PubMed ID: 12917818
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
Cripps MC; Figueredo AT; Oza AM; Taylor MJ; Fields AL; Holmlund JT; McIntosh LW; Geary RS; Eisenhauer EA
Clin Cancer Res; 2002 Jul; 8(7):2188-92. PubMed ID: 12114419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
